In terms of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 the Management Discussion and Analysis Report (MDAR) is structured as follows:
- Economic Outlook
- Industry structure and developments
- Opportunities
- Segment-wise or product-wise performance
- Outlook
- Threats, Risk and Concerns
- Internal Control System
- Financial and operational performance
- Material Development in Human Resources
- details of significant changes (i.e. change of 25% or more as compared
to the immediately previous financial year) in key financial ratios, along with detailed
explanations therefore, including:
(i) Debtors Turnover
(ii) Inventory Turnover
(iii) Interest Coverage Ratio
(iv) Current Ratio
(v) Debt Equity Ratio
(vi) Operating Profit Margin
(vii) Net Profit Margin
or sector-specific equivalent ratios, as applicable.
- details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof.
Some Statements in this discussion may be forward looking. The Companys actual results, performance or achievements can thus differ materially from those projected in any such forward-looking statements in the management discussion and analysis on account of various factors such as changes in Government regulations, tax regimes, impact of competition, etc.
Economic Outlook:
Amid persistent global economic headwinds, India stands out as one of the fastest-growing
major economies. According to the First Advance Estimates of Gross Domestic Product
2025-26, Indias GDP growth is projected at 7.4% in FY 2025-26, compared to 6.5% in FY
2024-25. Robust private consumption, tax reforms, and resilient manufacturing and services
activity are supporting the growth trajectory. Despite rising trade tensions and policy
uncertainty, Indias economic outlook remains resilient, with growth estimated at 6.5% in
FY 2026-27 and 6.6% in FY 2027-28. Key drivers include easing inflationary pressures,
rapid infrastructure development and digitization, a recovery in exports and private
investments, and favorable policy reforms, among others.
Industry Structure and Developments:
Indian Pharmaceutical Industry
The Indian pharmaceutical industry was valued at approximately USD 55 billion in 2025 and
is expected to reach USD 120-130 billion by 2030, growing at a CAGR of 11-13%. Growth will
be driven by a combination of expanding healthcare access, growing demand for treatments
across both acute and chronic conditions, digital transformation, and continued reliance
on affordable generic medicines. India ranks as the third-largest pharmaceutical producer
globally, by volume, and the 14th largest by value, contributing around 1.72% to Indias
GDP. The strength of the industry lies in its well-established generics ecosystem,
cost-effective manufacturing, and a large pool of skilled scientists and engineers.
Indias pharmaceutical sector has a strong export presence, supplying medicines to over
200 countries worldwide, with the United States (US) being its largest export destination.
Pharmaceutical exports have grown steadily from USD 15 billion in FY 2013-14 to USD 27.9
billion in FY 2023-24 and USD 30.47 billion in FY 2024-25. Generic drugs account for 20%
of global exports in terms of volume, positioning the country as the largest provider of
generic medicines globally.
In the Union Budget 2026-27, the government launched the Biopharma SHAKTI (Strategy for
Healthcare Advancement), with an outlay of Rs. 10,000 crores over the next five years,
aimed at positioning India as a global hub for biopharmaceutical manufacturing and
innovation. This initiative reflects the growing shift in Indias disease burden toward
non-communicable diseases, such as diabetes, underscoring the importance of biologic
medicines in improving patient outcomes.
Looking ahead, the Indian Pharmaceutical industry is poised for robust growth, with the
market projected to reach USD 450 billion by 2047. This expansion will be supported by
favorable government policies, rising prevalence of chronic diseases, increasing foreign
investments, and a strong focus on the manufacturing of high-quality pharmaceutical
products.
GROWTH DRIVERS
Increase in Chronic Diseases: Rising incidences of chronic diseases such
as hypertension, diabetes, respiratory ailments, and cardiovascular diseases on account of
rapid urbanization, aging population, adoption of sedentary lifestyles, and poor dietary
habits are expected to boost demand for pharmaceutical products.
Improving Affordability: Increasing income levels and affluence are
prompting individuals to seek high-quality healthcare services, including better
hospitals, medicines, and treatment.
Expanding Insurance Coverage: Health insurance penetration in India
continues to deepen, supported by greater participation from private insurers and broader
therapy coverage. The governments Ayushman Bharat Pradhan Mantri Jan Arogya Yojana
(AB-PMJAY) health insurance scheme is driving healthcare access for patients.
Government Support and Incentives: Supportive government policies, such
as the Production Linked Incentive (PLI) scheme, stringent quality and regulatory
standards, and focus on chronic diseases, are further propelling the pharmaceutical
industrys growth.
Company performance: Until the previous financial year, the
Company was primarily engaged in the trading of pharmaceutical products. During the year
under review, the Company expanded its business operations by acquiring a 51% equity stake
in Calborn Lifescience Private Limited, thereby making it a subsidiary of the Company.
This strategic acquisition marks the Companys entry into the pharmaceutical manufacturing
segment, strengthening its presence across the healthcare value chain. Calborn Lifescience
Private Limited is engaged in the manufacturing of a unique portfolio of Vitamin D3
products and has established itself as one of the leading manufacturers in this niche
segment. Notably, Calborn is recognized as the second manufacturer in India for this
product category, providing the Company with a competitive advantage and opportunities for
growth in the domestic and international markets.
The acquisition aligns with the Companys long-term strategy of diversifying its
operations, enhancing value addition, and creating a stronger and more integrated business
model. The Company expects this expansion into manufacturing to contribute positively to
its future growth, profitability, and market positioning.
During the current financial year, the total income of the Company was Rs. 5680.62 Lakhs
during current year as against Rs. 6763.75 Lakhs in the previous year. The Company has
reported net profit of Rs. 218.36 Lakhs during the year under review as against profit of
Rs. 256.58 Lakhs in the previous year. Your Board is looking more confident to increase
revenue and profit in coming years.
Opportunities and Threats:
Being a Trading company, our company is exposed to specific risks that are particular to
its business and the environment within which it operates including interest rate
volatility, economic cycle, and market risk. Further, venturing into new verticals and
products shall also expose your company to risk. However, these also give an opportunity
to exponentially grow the business.
Business Performance:
During the current financial year, the total income of the Company was Rs. 5680.62 Lakhs
during current year as against Rs. 6763.75 Lakhs in the previous year. The Company has
reported net profit of Rs. 218.36 Lakhs during the year under review as against profit of
Rs. 256.58 Lakhs in the previous year. Your Board is looking more confident to increase
revenue and profit in coming years.
Outlook:
With the current promoters and management at the helm, your company is hopeful about the
expansion of the business operations. Improving economic scenarios, growing consumption
and demand shall create more opportunities.
It is expected that the economic conditions shall improve.
Risks and areas of concern:
Our strength is our determination and team work, weakness is the low equity base,
opportunities are multiples and threats are the vibrations in the economy and government
policies.
In any business, risks and prospects are inseparable. As a responsible management, the
Companys principal Endeavour is to maximize returns. The Company continues to take all
steps necessary to minimize its expenses through detailed studies and interaction with
experts.
Internal control systems and their adequacy:
The Company has carried out the internal audit and has ensure that recording and reporting
are adequate and proper, the internal controls exist in the system and that sufficient
measures are taken to update the internal control system. The system also ensures that all
transactions are appropriately authorized, recorded and reported. Exercises for
safeguarding assets and protection against unauthorized use are undertaken from time to
time. The Companys audit Committee reviewed the internal control system. All efforts are
being made to make the internal control systems more effective. All these measures are
continuously reviewed by the management and as and when necessary, improvements are
affected.
Material developments in human resources/industrial relations front,
including number of people employed:
The company had sufficient numbers of employees at its registered office. The company
recognizes the importance of human value and ensures that proper encouragement both moral
and financial is extended to employees to motivate them. The company enjoyed excellent
relationship with workers and staff during the year under review.
details of significant changes (i.e. change of 25% or more as compared to
the immediately previous financial year) in key financial ratios, along with detailed
explanations therefore, including:
There were following changes in the below-mentioned ratios which may or may not be 25% or
more as compared to the immediately previous financial year:
(i) Debtors Turnover 2.68:1 as compared to 3.56:1 of previous year.
(ii) Inventory Turnover 18.07:1 as compared to 14.93:1 of previous year.
(iii) Interest Coverage Ratio 2.87:1 as compared to 6.32:1 of previous year.
(iv) Current Ratio 2.37:1 as compared to 5.31:1 of previous year.
(v) Debt Equity Ratio 0.65:1 as compared to 0.52:1 of previous year.
(vi) Operating Profit Margin (%) 16.11% as compared to 16.47% of previous year.
(vii) Net Profit Margin (%) 4.01% as compared to 3.82% of previous year.
or sector-specific equivalent ratios, as applicable.
details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof 0.09:1 as compared to 0.08:1 of previous year.
Cautionary Statement: Certain statements in the above Report may be forward looking and are stated as required by the legislations in force. The actual results may be affected by various factors that differ from what is anticipated in terms of future performance and the outlook presented above.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.